acute myeloid leukaemia

News

Kura files $100m offer after menin inhibitor results in AML...

The development of Kura Oncology’s menin inhibitor ziftomenib for acute myeloid leukaemia has been held back by safety concerns in the past, but new data suggests the prog

News

Actinium radioligand aces AML trial as filings beckon

Survival doubled when Iomab-B was used as a conditioning regimen before a stem cell transplant.

News

Actinium eyes filing as conditioning drug for AML aces trial

Actinium Pharma is on course to submit its targeted radiotherapy for acute myeloid leukaemia (AML) patients needing a bone mar

News

Pleco raises €17m for tumour microenvironment drug

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to

News

EHA: Survival data sets Daiichi Sankyo's quizartinib back on...

Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the U

News

FDA clears new first-line use for Servier's Tibsovo in AML

Servier is on course to get a return on its $1.8 billion takeover of Agios Pharma's oncology business after getting a key FDA approval for Tibsovo, the main asset in the deal.

Kura files $100m offer after menin inhibitor results in AML...

Actinium radioligand aces AML trial as filings beckon

Actinium eyes filing as conditioning drug for AML aces trial

Pleco raises €17m for tumour microenvironment drug

EHA: Survival data sets Daiichi Sankyo's quizartinib back on...

FDA clears new first-line use for Servier's Tibsovo in AML

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

acute myeloid leukaemia

Editor's Picks